Most real-world semaglutide and tirzepatide users stop within a year, study finds
A medRxiv preprint of 743,153 US adults found 12-month persistence of 29.9% on semaglutide and 35.9% on tirzepatide, with weight loss best among those who stayed on.
Recap by typeshit. Full story at medRxiv.